Related Experiment Video
Updated: May 28, 2026

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
Published on: June 13, 2021
Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance
Lide Arana1, Andrea Guridi2, Elena Sevillano2
1Department of Applied Chemistry, University of the Basque Country EHU, 20018 Donostia, Spain.
Abstract:
Fungal infections represent an escalating global health challenge due to their increasing incidence, the emergence of multidrug-resistant pathogens, and the limited development of new antifungal agents. Therapeutic efficacy is compromised by mutations in drug targets, overexpression of efflux pumps, alterations in the ergosterol biosynthetic pathway, biofilm-associated tolerance, and extensive genomic plasticity. The growing prevalence of antifungal resistance and the limited availability of effective therapeutic options highlight the urgent need to strengthen epidemiological surveillance and accelerate research into innovative therapeutic strategies. In this review, we discuss the potential of lipid-based drug delivery systems (LDDSs) as a versatile strategy to optimize antifungal administration and overcome resistance mechanisms. Liposomes (LPs), solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid nanoparticles (LNPs) offer high biocompatibility, efficient encapsulation of hydrophobic compounds, structural stability, and controlled drug release. Their nanoscale properties facilitate penetration into biofilms, promote intracellular uptake, and reduce the impact of efflux-mediated drug extrusion, thereby improving cellular penetration and circumventing resistance pathways. In addition, LDDSs increase bioavailability, reduce toxicity, and promote drug accumulation within poorly accessible tissue compartments. Overall, LDDSs represent a promising approach to expand the therapeutic arsenal against both superficial and invasive fungal infections, particularly those caused by multidrug-resistant pathogens.
Insights
Lipid-based drug delivery systems (LDDSs) offer a promising strategy to combat rising antifungal resistance. These systems enhance drug efficacy and overcome resistance mechanisms in fungal infections.
Area of Science:
- Mycology
- Nanotechnology
- Pharmacology
Background:
- Fungal infections pose a growing global health threat due to increasing incidence and multidrug-resistant strains.
- Therapeutic challenges include drug target mutations, efflux pumps, biofilm tolerance, and limited new antifungal development.
- Antifungal resistance necessitates novel therapeutic strategies and improved epidemiological surveillance.
Purpose of the Study:
- To review the potential of lipid-based drug delivery systems (LDDSs) for optimizing antifungal administration.
- To explore how LDDSs can overcome key antifungal resistance mechanisms.
- To highlight LDDSs as a strategy against challenging fungal infections.
Main Methods:
- Review of current literature on fungal infections, antifungal resistance, and lipid-based drug delivery systems.
- Discussion of various LDDS formulations including liposomes (LPs), solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid nanoparticles (LNPs).
- Analysis of the physicochemical properties and biological advantages of LDDSs in antifungal therapy.
Main Results:
- LDDSs exhibit high biocompatibility, stability, and controlled release properties.
- Nanoscale properties of LDDSs facilitate biofilm penetration, enhance intracellular uptake, and reduce efflux pump activity.
- LDDSs improve drug bioavailability, reduce toxicity, and promote tissue accumulation.
Conclusions:
- LDDSs represent a versatile strategy to enhance antifungal drug efficacy and overcome resistance.
- These systems show potential in treating both superficial and invasive fungal infections, especially those caused by resistant pathogens.
- Further development of LDDSs is crucial to expand the therapeutic arsenal against fungal diseases.
Related Concept Videos
Antifungal Agents
Bioavailability Enhancement: Drug Permeability Enhancement
Oral Drug Delivery Systems: Introduction
Modified-Release Drug Delivery Systems: Site-Targeted
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Influencing Factors
